+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 2 Actively Recruiting clinical trials

R

Actively Recruiting

Researchers are studying the safety and effectiveness of RTN-001, a modified release drug, in adults aged 18 to 75 years with uncontrolled and resistant hypertension, defined as systolic blood pressure SBP of 135 mm Hg or higher and diastolic blood pressure DBP of 80 mm Hg or higher. This Phase 2b trial is randomized, double-blind, and involves multiple centers. The study includes three main periods Screening, Run-in, and Treatment. During the trial, about 280 eligible participants will be randomly assigned equally into four groups to receive one of three doses of RTN-001 15 mg, 30 mg, or 45 mg or a matching placebo. The treatment lasts for 12 weeks. After the treatment period ends, participants will have an off-treatment follow-up visit two weeks later to assess their condition. Participants will be involved in various assessments throughout the study, including blood pressure measurements taken at multiple time points during and after treatment. Researchers will monitor changes in systolic and diastolic blood pressure using office measurements, central blood pressure readings, and ambulatory monitoring. Safety and efficacy will be evaluated through these repeated measures, and adherence to the study drug will be tracked. The total participation includes screening, run-in, treatment, and follow-up visits spanning several months.

Age: 18Years - 75YearsAll GendersPhase 2
44 locations
L

Actively Recruiting

Researchers are evaluating the safety and effectiveness of Tumor Treating Fields TTFields given with pembrolizumab and platinum-based chemotherapy in patients with advanced non-small cell lung cancer NSCLC that has spread to other parts of the body. This study, called LUNAR-2, compares this combination to pembrolizumab and chemotherapy alone, focusing on overall survival and progression-free survival. It also examines outcomes based on the specific subtype of lung cancer and PD-L1 expression levels. Participants receive either the combination of TTFields delivered by the portable NovoTTF-200T device, pembrolizumab, and platinum-based chemotherapy, or pembrolizumab and chemotherapy without TTFields. The NovoTTF-200T device delivers electric fields to disrupt cancer cell division and is used continuously at home. Treatments are given according to a randomized, open-label design. During the study, participants will be monitored regularly with evaluations of survival and disease progression for up to six years. Researchers will track response rates, duration of response, disease control, and adverse events. Assessments include measuring cancer status by standardized criteria. This long-term follow-up helps understand the effects and safety of the treatments over time.

Age: 18Years +All GendersPhase 3
104 locations